NPM1 and acute myeloid leukemia: In one study of younger patients with newly diagnosed NPM1-mutated AML, cumulative incidence of relapse (CIR) for patients with detectable MRD after double induction was 53.0% at 4 years versus only 6.5% for those with undetectable MRD (P < 0.001) [56].